Literature DB >> 21504290

Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified.

Pier Luigi Zinzani, Cinzia Pellegrini, Alessandro Broccoli, Vittorio Stefoni, Letizia Gandolfi, Federica Quirini, Lisa Argnani, Emilio Berti, Enrico Derenzini, Stefano Pileri, Michele Baccarani.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21504290     DOI： 10.3109/10428194.2011.573031

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  11 in total

Review 1.  Update: peripheral T-cell lymphomas.

Authors:  Kerry J Savage
Journal:  Curr Hematol Malig Rep       Date:  2011-12       Impact factor: 3.952

2.  A retrospective clinical analysis of Japanese patients with peripheral T-cell lymphoma not otherwise specified: Hokkaido Hematology Study Group.

Authors:  Yoshihiro Torimoto; Kazuya Sato; Katsuya Ikuta; Toshiaki Hayashi; Yasuo Hirayama; Junki Inamura; Hajime Kobayashi; Ryoji Kobayashi; Kyuhei Koda; Mitsutoshi Kurosawa; Akio Mori; Shuichi Ota; Hajime Sakai; Akio Shigematsu; Motohiro Shindo; Hitoshi Shinzaki; Fumihiko Takahashi; Rishu Takimoto; Junji Tanaka; Satoshi Yamamoto; Yutaka Kohgo; Takashi Fukuhara
Journal:  Int J Hematol       Date:  2013-06-29       Impact factor: 2.490

3.  Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: Results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registry.

Authors:  Robert N Stuver; Niloufer Khan; Marc Schwartz; Mark Acosta; Massimo Federico; Christian Gisselbrecht; Steven M Horwitz; Frederik Lansigan; Lauren C Pinter-Brown; Barbara Pro; Andrei R Shustov; Francine M Foss; Salvia Jain
Journal:  Am J Hematol       Date:  2019-04-09       Impact factor: 10.047

4.  Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities.

Authors:  Athena Kritharis; Michael Coyle; Jaya Sharma; Andrew M Evens
Journal:  Blood       Date:  2015-03-03       Impact factor: 22.113

Review 5.  Peripheral T cell lymphomas: from the bench to the clinic.

Authors:  Danilo Fiore; Luca Vincenzo Cappelli; Alessandro Broccoli; Pier Luigi Zinzani; Wing C Chan; Giorgio Inghirami
Journal:  Nat Rev Cancer       Date:  2020-04-06       Impact factor: 60.716

Review 6.  From empiric to mechanism-based therapy for peripheral T cell lymphoma.

Authors:  Andrew M Intlekofer; Anas Younes
Journal:  Int J Hematol       Date:  2014-02-08       Impact factor: 2.490

7.  Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi.

Authors:  Annalisa Chiappella; Alessandra Tucci; Alessia Castellino; Vincenzo Pavone; Ileana Baldi; Angelo Michele Carella; Lorella Orsucci; Manuela Zanni; Flavia Salvi; Anna Marina Liberati; Gianluca Gaidano; Chiara Bottelli; Bernardo Rossini; Sonia Perticone; Pasqualina De Masi; Marco Ladetto; Giovannino Ciccone; Antonio Palumbo; Giuseppe Rossi; Umberto Vitolo
Journal:  Haematologica       Date:  2013-06-28       Impact factor: 9.941

8.  Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts.

Authors:  Neha Mehta-Shah; Matthew A Lunning; Alison J Moskowitz; Adam M Boruchov; Jia Ruan; Peggy Lynch; Paul A Hamlin; John Leonard; Matthew J Matasar; Patricia L Myskowski; Evan Marzouk; Sumithra Nair; Tamir Sholklapper; Veena Minnal; Maria L Palomba; James Vredenburgh; Anita Kumar; Ariela Noy; David J Straus; Andrew D Zelenetz; Heiko Schoder; Jurgen Rademaker; Wendy Schaffer; Natasha Galasso; Nivetha Ganesan; Steven M Horwitz
Journal:  Am J Hematol       Date:  2021-07-29       Impact factor: 10.047

Review 9.  Expanding role of lenalidomide in hematologic malignancies.

Authors:  Nilanjan Ghosh; Michael R Grunwald; Omotayo Fasan; Manisha Bhutani
Journal:  Cancer Manag Res       Date:  2015-05-02       Impact factor: 3.989

10.  The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas.

Authors:  R Briski; A L Feldman; N G Bailey; M S Lim; K Ristow; T M Habermann; W R Macon; D J Inwards; J P Colgan; G S Nowakowski; M S Kaminski; T E Witzig; S M Ansell; R A Wilcox
Journal:  Blood Cancer J       Date:  2014-05-30       Impact factor: 11.037
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.